ZBIO Latest News, Press Relases and Analysis

All

Press Releases

13 days ago - By: Purcell & Lefkowitz LLP

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Zenas BioPharma, Inc. (NASDAQ: ZBIO)

21 days ago - By: Zenas BioPharma

Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update

21 days ago - By: Zenas BioPharma

Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update

22 days ago - By: Zenas BioPharma

Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences

22 days ago - By: Zenas BioPharma

Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences

a month ago - By: Benzinga - Mentions: DYN PRE GNTA RNA ...

12 Health Care Stocks Moving In Monday's Intraday Session

a month ago - By: Benzinga - Mentions: DYN PRE GNTA RNA ...

12 Health Care Stocks Moving In Monday's Pre-Market Session

a month ago - By: Zenas BioPharma

Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis

a month ago - By: Zenas BioPharma

Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis

2 months ago - By: The Motley Fool

Chairman and CEO of Zenas BioPharma (ZBIO) Buys 36,928 Shares for $769,948

2 months ago - By: Zenas BioPharma

Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis

2 months ago - By: Zenas BioPharma

Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis

3 months ago - By: Zenas BioPharma

Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million

3 months ago - By: Zenas BioPharma - Mentions: RPRX

Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million

3 months ago - By: Zenas BioPharma

Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences

3 months ago - By: Zenas BioPharma

Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences

4 months ago - By: Zenas BioPharma

Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

4 months ago - By: Zenas BioPharma

Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

6 months ago - By: Zenas BioPharma

Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

6 months ago - By: Zenas BioPharma

Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

6 months ago - By: The Schall Law Firm

ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm

6 months ago - By: Faruqi & Faruqi, LLP

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma

6 months ago - By: The Gross Law Firm

June 16, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against ZBIO

6 months ago - By: DJS Law Group LLP

FINAL ALERT NOTICE - ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO

6 months ago - By: Faruqi & Faruqi, LLP

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma

6 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO

6 months ago - By: THE ROSEN LAW FIRM, P. A.

ZBIO Deadline: ZBIO Investors with Losses in Excess of $100K Have Opportunity to Lead Zenas BioPharma, Inc. Securities Lawsuit Filed by The Rosen Law Firm

6 months ago - By: Levi & Korsinsky, LLP

Zenas BioPharma, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ZBIO

6 months ago - By: Faruqi & Faruqi LLP

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma

6 months ago - By: Robbins Geller Rudman & Dowd LLP

MONDAY INVESTOR DEADLINE: Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit - ZBIO

6 months ago - By: The Gross Law Firm

Investors who lost money on Zenas BioPharma, Inc.(ZBIO) should contact The Gross Law Firm about pending Class Action - ZBIO

6 months ago - By: DJS Law Group LLP

ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO

6 months ago - By: The Rosen Law Firm PA

ZBIO DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel Before Important June 16 Deadline in Securities Class Action First Filed by the Firm – ZBIO

6 months ago - By: Faruqi & Faruqi, LLP

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma

6 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO

ZENAS BIOPHARMA INC (ZBIO) Stock News

ZBIO Latest News, Press Relases and Analysis